ActinomycinD |
Topoisomerase and transcription inhibitor |
ND |
p53, DRAM |
RKO Colon Carcinoma |
DRAM siRNA; ATG5 siRNA |
Increased clonogenic survival |
14 |
Camptothecin |
Topoisomerase inhibitor |
HR, NHEJ |
p53, ULK1/ULK2 |
U2OS Osteosarcoma |
ATG13 shRNA |
Increased clonogenic survival |
13 |
Doxorubicin |
Topoisomerase inhibitor |
HR, NER, NHEJ |
PARP-1 |
3T3 MEFs |
Beclin 1 and ATG5 siRNA; 3-MA, CQ |
Increased death(Trypan Blue) |
54 |
6-Thioguanine |
Nucleoside analog |
MMR, BER |
MLH1, MSH2, p53, mTOR, BNIP3 |
HCT116 colon carcinoma and HEC59 endometrial cancer |
ATG5 shRNA |
Increased apoptosis |
136 |
BO-1051 |
Alkylating agent |
ND |
ATM |
HA227/VGH Mahlavu Hepatomas |
Bafilomycin A1, beclin shRNA |
Reduced Viability (MTT) |
132 |
Temozolomide |
Alkylating agent |
MMR, BER, MGMT |
ATM, TSC2, mTORC1 |
LN-229 and U87 gliomas |
3-MA |
Increased apoptosis |
137 |
MNNG, N-methyl-N′-nitro-N-nitrosoguanidine; |
Alkylating agent |
MMR, BER, MGMT |
ND |
Lymphomas |
CQ, ATG5 shRNA |
Reduced cell number |
138 |
Cisplatin |
Alkylating-like agent |
MMR, NER, HR, NHEJ |
ATM |
HA227/VGH Mahlavu Hepatomas |
Beclin 1 shRNA |
Reducedviability (MTT) |
132 |
5-methoxyflavanone |
Methoxylated flavone |
ND |
MEK |
HCT116 Colon Carcinoma |
3-MA; bafilomycin A1 |
Reduced clonogenic survival |
139 |
UVB |
Electromagnetic radiation |
NER |
AMPK, ULK1 |
MEFs |
ATG5 KO 3MA |
Increased apoptosis |
96 |